Cash-strapped Bluebird Bio To Be Sold For Less Than US$30M Upfront
By Anna Bratulic Bluebird bio is set to go private in a buyout by private equity firms Carlyle and SK Capital Partners, ending its turbulent run as a public company amid ongoing financial struggles. Once seen as a trailblazer in the gene therapy space, bluebird has faced mounting challenges, including shuttering its European operations after failed pricing talks for its products, and a warning about its financial viability three years ago. In 2024, it slashed about a quarter of its workforce to sustain key programmes, including its US$3.1-million sickle-cell disease...
